Apyx Medical Q3 revenue down 23% YoY; cuts full-year 2022 guidance

Apyx Medical Corp

2022-Q3 EPS reported -$0.50 revenue$31,899,000

Total revenue $9.1M (-23% YoY); Advanced Energy revenue $7.1M (-31% YoY).
Net loss $5.8M ($0.17/share) vs $4.2M loss in Q3 2021; Adjusted EBITDA loss $3.9M.
Full-year 2022 revenue guidance cut to $44.8M-$47.9M from prior $51.0M-$56.4M.
Company cites continued disruption from March FDA Safety Communication as primary headwind.
OEM revenue grew 34% to $2.0M, partially offsetting Advanced Energy decline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apyx Medical Corp reported third quarter ended September 30, 2022 results: revenue $9.1 million, net income Net loss attributable to stockholders of $5.8 million. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $9.1 million
Net income: Net loss attributable to stockholders of $5.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

third quarter ended September 30, 2022, and updated financial expectations for the full year ending December 31, 2022. Third Quarter 2022 Financial Summary : • Total revenue of $9.1 million, down 23% year-over-year. ◦ Advanced Energy revenue of $7.1 million, down 31% year-over-year. ◦ OEM revenue of $2.0 million, up 34% year-over-year. • Net loss attributable to

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-22-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.